000009970 001__ 9970
000009970 005__ 20240124114332.0
000009970 0247_ $$2DOI$$a10.6083/v405sb22w
000009970 037__ $$aETD
000009970 245__ $$aTrikafta® modulator therapy and glycemic status in pediatric patients with cystic fibrosis
000009970 260__ $$bOregon Health and Science University
000009970 269__ $$a2022
000009970 336__ $$aThesis
000009970 502__ $$bM.S.
000009970 520__ $$aThe development of cystic fibrosis-related diabetes may negatively affect lung health, nutrition and growth status, and mental health of individuals with cystic fibrosis. In this retrospective medical record review study, we will assess changes in glycemic status before and after initiating Trikafta® modulator therapy by utilizing biochemical indicators of glucose homeostasis (hemoglobin A1C, oral glucose tolerance test (OGTT), fasting glucose). We will also assess changes in body mass index (BMI) and lung function (pFEV1) in relation to initiation of Trikafta®. Following analysis of changes within categories, we will then investigate associations between lung function, anthropometrics, and glycemic status to understand the interrelationships between these components of health. The overall goal of this study is to assess the long-term effects of Trikafta® on glycemic status in pediatric patients (ages 11-21 years) with cystic fibrosis.
000009970 650__ $$aChild$$016462
000009970 650__ $$aAdolescent$$014285
000009970 650__ $$aGlucose Tolerance Test$$019585
000009970 650__ $$a Cystic Fibrosis$$017315
000009970 650__ $$aDiabetes Mellitus$$017671
000009970 650__ $$a Glycated Hemoglobin$$020045
000009970 6531_ $$atrikafta
000009970 691__ $$aSchool of Medicine$$041369
000009970 7001_ $$aMerrill, Courtney
000009970 8564_ $$931569dec-e829-4c35-99c6-dcdd967f8280$$s1854987$$uhttps://digitalcollections.ohsu.edu/record/9970/files/Merrill.Courtney.2022.pdf
000009970 905__ $$a/rest/prod/v4/05/sb/22/v405sb22w
000009970 909CO $$ooai:digitalcollections.ohsu.edu:9970$$pstudent-work
000009970 980__ $$aTheses and Dissertations